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Abstract
The Suppressor of Fused (SUFU) protein plays an essential role in the Hedgehog (HH) signaling pathway, by regulation of
the GLI transcription factors. Two major isoforms of human SUFU are known, a full-length (SUFU-FL) and a carboxy-terminal
truncated (SUFU- DC) variant. Even though SUFU- DC is expressed at an equivalent level as SUFU-FL in certain tissues, the
function of SUFU-DC and its impact on HH signal transduction is still unclear. In two cell lines from rhabdomyosarcoma, a
tumor type associated with deregulated HH signaling, SUFU-DC mRNA was expressed at comparable levels as SUFU-FL
mRNA, but at the protein level only low amounts of SUFU-DC were detectable. Heterologous expression provided support
to the notion that the SUFU-DC protein is less stable compared to SUFU-FL. Despite this, biochemical analysis revealed that
SUFU-DC could repress GLI2 and GLI1DN, but not GLI1FL, transcriptional activity to the same extent as SUFU-FL. Moreover,
under conditions of activated HH signaling SUFU-DC was more effective than SUFU-FL in inhibiting GLI1DN. Importantly, co-
expression with GLI1FL indicated that SUFU-DC but not SUFU-FL reduced the protein levels of GLI1FL. Additionally, confocal
microscopy revealed a co-localization of GLI1FL with SUFU-DC but not SUFU-FL in aggregate structures. Moreover, specific
siRNA mediated knock-down of SUFU-DC resulted in up-regulation of the protein levels of GLI1FL and the HH signaling
target genes PTCH1 and HHIP. Our results are therefore suggesting the presence of novel regulatory controls in the HH
signaling pathway, which are elicited by the distinct mechanism of action of the two alternative spliced SUFU proteins.
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Introduction
The Hedgehog (HH) signaling pathway is fundamental during
embryonic development, and is also implicated in the growth of a
variety of tumors [1]. The HH proteins are secreted ligands, which
bind to the Patched 1 (PTCH1) receptor and initiate additional
signaling events, ultimately resulting in the activation of the GLI
transcription factors. The intracellular protein Suppressor of Fused
(SUFU) acts as a negative regulator in the pathway, by binding to
the GLI factors in the absence of signal activity and thereby
repressing their transcriptional effects [2]. SUFU sequesters GLI1
in the cytoplasm but can also bind to GLI1 on DNA and actively
export the nuclear GLI1 protein [3]. Additionally, SUFU binds to
the other two GLI proteins, GLI2 and GLI3, and has recently
been shown to be an important regulator of GLI2 and GLI3
processing, promoting the production of the truncated repressors
[4,5]. HH stimulation triggers the dissociation of SUFU-GLI
complexes [4,6]. The mechanism whereby the HH signal
counteracts the repression of SUFU on GLI activity may also
involve the ubiquitin-proteasome pathway-mediated degradation
of SUFU [7].
Loss of function of mammalian SUFU leads to ligand-
independent activation of the HH pathway [8]. Mutations in
human SUFU have been found in medulloblastoma [9] and
prostate cancer [10], and SUFU loss of heterozygosity was
observed in rhabdomyosarcoma (RMS) [11], implicating that
SUFU is a tumor suppressor gene.
Human SUFU is localized on chromosome 10q24–25, and
contains 12 exons [12]. In addition to the full-length 484 amino
acids (aa) protein, SUFU-FL, several alternatively spliced variants
of SUFU have previously been identified. One of them codes for a
carboxy-terminal deleted isoform of 433 aa, reducing therefore the
calculated molecular mass from 54 to 48 kDa [13]. The truncated
SUFU, SUFU-DC, uses a unique terminal exon harboring an
early in-frame translation termination codon, exon 10a, which is
derived from sequences within intron 10 of SUFU (Fig 1A).
Most studies have focused on SUFU-FL, while the function of
SUFU-DC remains unclear. The aim of this work has been to
analyze the biological properties of SUFU-DC and its implications
on the transduction of the HH signal. These experimental
approaches provide now support for a functional role of SUFU-
DC and have resulted in the identification of novel mechanisms
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GLI transcription factors.
Results
Expression of SUFU Splice Variants
We first investigated the expression of SUFU in normal tissue
and cancer cell lines by real-time RT-PCR (Fig 1B). SUFU-DC
was generally expressed at lower levels than SUFU-FL, however in
the lung comparable amounts of the variants were detected and in
the lung cancer cell line GI117 higher levels of SUFU-DC relative
to SUFU-FL could be observed. We also evaluated the expression
pattern in RMS, a tumor associated with deregulated HH
signaling [11,14]. A variable expression was seen among the
RMS cell lines, with most having a higher expression of SUFU-FL
than SUFU-DC, however in CCA and RMS13 cells the levels
were comparable (Fig 1C). To investigate whether the SUFU-DC
protein can be detected, we first transfected NIH3T3 cells with an
expression construct of SUFU-DC followed by whole cell protein
extractions. On Western blot analysis a protein band of the
expected 48 kDa size was observed with the SUFU-DC transfected
construct, which was absent with the empty vector (Fig 1D). To
examine whether it was possible to detect endogenous levels of
SUFU-DC, the RMS13, CCA and Rh36 cell lines were also used.
In contrast to the abundant protein expression of SUFU-FL in
these cells, low levels of a protein band co-migrating with SUFU-
DC at the 48 kDa region were detected in the RMS13 and CCA
cell lines (Fig 1D). Interestingly, in the Rh36 cells, which have
reduced SUFU-DC mRNA expression, no SUFU-DC protein was
observed. Thus, even though the mRNA levels of the SUFU
variants in either RMS13 or CCA cells are similar, the amounts of
the corresponding proteins are dissimilar, with only low levels of
SUFU-DC detected.
Expression of SUFU-DC and SUFU-FL Constructs in
Hek293 Cells
To examine whether the differences in endogenous protein
levels of the SUFU variants in the human RMS cell lines are
also reflected on exogenously added proteins, Hek293 cells were
transfected with SUFU-FL and SUFU-DC expression constructs.
Indeed, the steady state levels of the exogenous SUFU variants
were in line with what has been observed for the endogenous
proteins, namely, reduced amounts of SUFU-DC relative to
SUFU-FL. Additionally, treatment of the transfected cells with
the proteasome inhibitor MG-132 conferred a detectable
increase in the expression levels of the SUFU-DC (Fig 2A).
Similarly, the endogenous SUFU-DC protein in RMS13 cells
was also increased by MG-132 treatment (Fig 2B). Worth noting
is that expression of the two isoforms in E.coli [15] revealed
much higher levels of SUFU-FL than SUFU-DC in the soluble
fraction (Figure S1). In conclusion, the heterologous expression
analysis of the SUFU variants in the human Hek293 cell line is
in agreement with the observations of low endogenous protein
levels of SUFU-DC compared with SUFU-FL in the human
RMS cells.
GLI repression by SUFU-DC: Reduced Activity Against
GLI1FL but not GLI1DN or GLI2
Despite the lower protein expression of SUFU-DC relative to
SUFU-FL, we set on to address the possible repressive function of
SUFU-DC on GLI activity by reporter assays in NIH3T3 cells. In
this mouse embryonic fibroblast cell line the protein expression of
the SUFU-DC and SUFU-FL constructs is not as different as seen
in Hek293 cells (Fig 3A). SUFU and GLI1 are known to bind to
each other in the N-terminal and in the C-terminal regions of both
proteins [16,17]. As expected, SUFU-FL was capable of effectively
repressing full length GLI1 (GLI1FL) transcriptional activity; on
the other hand SUFU-DC could not act as an equally efficient
repressor (Fig 3B). This suggests a role of the last 51 amino acids of
SUFU in partially mediating the repression on GLI1FL. However,
when a GLI1 variant lacking the N-terminal region, GLI1DN
[18], was used, the repression elicited by either SUFU-FL or
SUFU-DC was comparable (Fig 3C).
Additionally, for GLI2 and the N-terminal-truncated active
form, GLI2DN, no major differences between the SUFU-FL and
SUFU-DC repressive effects could be observed (Fig 3D and E).
Effect of Introduction of SUFU-DC into Sufu2/2 MEFs
To further evaluate the functional capacity of SUFU-DCi n
relation to SUFU-FL we introduced the two expression constructs
into mouse embryonic fibroblasts lacking Sufu (Sufu2/2 MEFs),
together with a GLI reporter construct. SUFU-FL was found to
have a stronger effect than SUFU-DC in reducing GLI activity
(Fig 4). Possibly, this may reflect the increased ratio of Gli1 to Gli2
in Sufu2/2 relative to wild type MEFs [8], which would be in line
with the over-expression experiments of Fig 3B and D.
HH Signal Dependency of SUFU Inhibitory Activity
We also investigated whether HH signaling activation may
modulate the SUFU repressive effects on GLI1. For this purpose
mouse embryonic fibroblast cells lacking Ptch1 (Ptch12/2 MEFs),
and therefore characterized by a constitutively active HH signaling
pathway, were used. The results indicated that the maximal
repression was observed with SUFU-FL acting on GLI1FL, as
seen with NIH3T3 cells. SUFU-DC, on the other hand, was found
to be more effective than SUFU-FL in repressing the GLI1DN
variant (Fig 5A and B).
Over-expression of SUFU-DC but not SUFU-FL Elicits a
Reduction in GLI1FL
Since the SUFU variants had differential effects on the
GLI1FL transcriptional activity we examined their impact on
the GLI1FL protein levels. Surprisingly, co-expression of
GLI1FL with SUFU-DC in Hek293 cells resulted in lower
amounts of GLI1FL relative to co-expression with either SUFU-
Figure 1. Expression of SUFU-FL and SUFU-DC in human tissues and cell lines. A, Schematic map of the SUFU exon 10 to exon 12 genomic
region. Exons are shown by open boxes and splicing events by thin lines. The translation termination codons TGA and TAG are indicated, while the
black and white triangles show the position of the PCR primers used. B, Real-time PCR analysis of SUFU-FL and SUFU-DC expression in a multiple
tissue/tumor cDNA panel. C, Real-time RT-PCR analysis of SUFU-FL and SUFU-DC expression in the E-RMS cell lines JR-1, RD, Rh36, CCA, CT-TC and the
A-RMS cell line RMS13. For both the B and C panels the data are presented as relative unit (RU) expression values, after normalization to the
housekeeping gene large ribosomal protein (RPLPO), which is given the value of 1. Error bars indicate the standard deviation. *, Statistical significant
difference, p,0,01, (Student’s t test). D, Western blot analysis of extracts from NIH3T3, transfected with an expression construct for SUFU-DC-FLAG, or
pCMV (vector), CCA, RMS13 and Rh36 cells, and detected with a SUFU antibody. Note that CCA and RMS13 but not Rh36 cells express a protein band
(arrowheads), which co-migrates with that of the transfected SUFU-DC FLAG-tagged construct (arrow), the small size difference apparently reflecting
the presence of a FLAG tag. The endogenous SUFU-FL protein is indicated by FL.
doi:10.1371/journal.pone.0037761.g001
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that the mechanism of inhibition of GLI1FL activity by SUFU-
DC may be fundamentally different to the one elicited by
SUFU-FL, and could involve an increased degradation of the
GLI1FL protein. Interestingly, the levels of GLI2 remained
unchanged in the same transfection setting (Figure S2),
highlighting the specificity of the GLI1FL and SUFU-DC
interaction. Additionally, the levels of endogenous GLI1FL in
RMS13 cells were investigated following transfection of the
SUFU variants. SUFU-DC, in contrast to SUFU-FL, conferred
a detectable reduction of the GLI1FL levels. This reduction is
not as high as seen with exogenous GLI1FL in Hek293,
apparently the result of the relatively low RMS13 transfection
efficiency (usually less than 50%), which allows the presence of
a large number of untransfected cells that express high levels of
GLI1FL. Moreover, the proteasome inhibitor MG-132 increased
the GLI1FL protein in both SUFU-DC and SUFU-FL
transfected cells. (Fig 6C and D).
Subcellular Localization of SUFU-DC
Confocal microscopy with Hek293 cells was utilized to
examine the subcellular localization of transfected SUFU-FL
and SUFU-DC. In line with previous reports [19,20] SUFU-FL
had a predominant cytoplasmic localization, and we also found
SUFU-DC to be mainly detected in the cytoplasm (Fig 7A, left
and middle panel). GLI1FL was detected in the nucleus (Fig 7A,
right panel), as shown previously [17], but there were several
cases where a cytoplasmic localization was also observed. Co-
expression of GLI1FL and SUFU-FL resulted in co-localization
in the cytoplasm (Fig 7B, upper panels). SUFU-DC also co-
localized with GLI1FL, however, predominantly in aggregate/
clump structures in close proximity to the nucleus (Fig 7B,
lower panels).
Knock-down of Endogenous SUFU-DC Increases GLI1FL
Protein Levels and Up-regulates HH Signaling Targets
To investigate the role of endogenous SUFU-DC, two shRNA
constructs targeting SUFU-DC (sh4 and sh5) were individually
introduced into the RMS13 cell line. Transfection of the shRNAs
did not alter the SUFU-FL expression levels, as determined by
real-time RT-PCR analysis, highlighting their specificity for
SUFU-DC (Fig 8A). Additionally, a detectable reduction of
SUFU-DC protein was observed by sh5 (Figure S3), with the
effect seen being less than that of the SUFU-DC mRNA.
Subsequently, the GLI1 protein levels were analyzed by Western
blotting. In line with the negative impact of SUFU-DC on the
Figure 2. Impact of proteasome inhibition on exogenous and endogenous SUFU. A, Western blot analysis of soluble protein fractions from
Hek293 cells, transfected with expression constructs for Myc-SUFU-FL (FL) or Myc-SUFU-DC( DC) and treated with or without 10 mM MG-132 for 6
hours. A Myc antibody was used for protein detection. Vinculin staining was used as a loading control. Note the higher levels of SUFU-FL protein
relative to that of SUFU-DC, which is shown by an arrow. B, Western blot analysis of extracts from RMS13 cells with or without 10 mM MG-132
treatment for 6 hours. A SUFU antibody was used for protein detection. Note the increase of the lower protein band (SUFU-DC) relative to the upper
protein band (SUFU-FL). For both the A and B panels duplicate experiments were performed and a quantification of the average protein levels is
shown to the right.
doi:10.1371/journal.pone.0037761.g002
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effective siRNA used (sh5) resulted in increased amounts of
GLI1FL protein (Fig 8B). Moreover, the HH signaling target gene
HHIP and the HH signaling regulated transcript variants of the
PTCH1 gene, PTCH1-1B and PTCH1-1C [21,22], were up-
regulated by the shRNA treatments. Interestingly, the extent of
up-regulation appeared to parallel the effectiveness of the two
shRNAs in down-regulating SUFU-DC. Additionally, the GLI1
mRNA was not significantly changed by the introduction of the
shRNAs (Fig 8C). Thus, our data provide evidence that
endogenous SUFU-DC can modulate HH signaling activity
through a mechanism that is distinct from that of SUFU-FL,
namely by reducing GLI1FL protein levels.
Discussion
Human SUFU plays an essential role during both normal
development and cancerous transformation. SUFU is known to
functionally regulate the GLI proteins, the ultimate effectors of the
HH pathway [3]. However, the exact role of human SUFU-FL is
still not fully deciphered, and even more so the function of the
alternatively spliced variant SUFU-DC.
Although both SUFU isoforms could be detected at the mRNA
level, only low levels of the endogenous SUFU-DC protein were
observed in the Western blot analysis of the RMS cell lines. This
indicates that the SUFU-DC is less stable than SUFU-FL. The
analysis of the heterologous expression of the SUFU variants in the
Hek293 cell line is in agreement with a reduced stability of SUFU-
DC relative to SUFU-FL in human RMS cells. Moreover,
treatment with the proteasome inhibitor MG-132 confers a
selective increase of both the endogenous and exogenous SUFU-
DC protein, however, the levels of SUFU-FL are not reached.
Consequently, one has to hypothesize that other mechanisms may
also have a role in the reduced steady state levels of SUFU-DC,
possibly lysosomal autophagy as recently implicated in Wnt
Figure 3. Dose-dependent SUFU repression of GLI activity in NIH3T3 cells. A. Western blot analysis of extracts from NIH3T3 cells,
transfected with expression constructs for the SUFU variants, and detected with a SUFU antibody. Due to the partial co-migration with endogenous
mouse Sufu, the SUFU-FL expression in the right lane was calculated by subtracting from the total signal the mouse Sufu signal. This was determined
based on the Sufu expression in the left lane following normalization with the tubulin internal control. Note that the quantitation revealed that the
level of SUFU-FL (right lane, upper protein band) is 188% the level of SUFU-DC (middle lane, lower protein band). B–E, Different amounts of Myc-
tagged SUFU-FL or SUFU-DC expression constructs were co-transfected with 50 ng GLI expression constructs (Panel B, GLI1FL; panel C, GLI1DN;
panel D, GLI2FL; panel E, GLI2DN), 12xGLIBS-luc and pRL-SV reporter plasmids, and the luciferase activity was measured. Error bars indicate the
standard deviation.
doi:10.1371/journal.pone.0037761.g003
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fibroblast cell line NIH3T3, the protein levels of transfected
SUFU-FL and SUFU-DC are not as pronouncedly different.
GLI2 is the primary activator of HH-dependent transcription.
Our biochemical analysis in NIH3T3 cells showed that SUFU-DC
could repress GLI2 transcriptional activity to the same extent as
SUFU-FL. These observations are in line with an earlier study,
which showed that a SUFU deletion construct lacking the amino
acids 389–485 was fully capable to repress GLI2, but to a lesser
extent GLI1 [20].In a previous study we have shown that GLI1 is
the most important GLI factor in E-RMS [24]. Now we provide
evidence that SUFU-FL has generally a higher capacity than
SUFU-DC in inhibiting GLI1 activity. However, in certain cellular
contexts SUFU-DC may have a major impact on the transcrip-
tional activation elicited by GLI1. For example, our data (Fig 5)
indicate that SUFU-DC is more effective than SUFU-FL in
inhibiting the transcriptional activity of an amino terminal variant
of GLI1, GLI1DN, during conditions of activated HH signaling.
On the other hand in Sufu2/2 MEFs, SUFU-FL elicited a
stronger inhibition than SUFU-DC on GLI activity (Fig 4),
possibly reflecting the increased amounts of Gli1 in these cells,
which would be consistent with the data of Fig 3B.
Importantly, the co-expression experiments of GLI1FL with the
SUFU variants suggest that distinct regulatory mechanisms act on
GLI1FL. SUFU-FL does not alter the protein levels of GLI1FL
but is quite effective in repressing its transcriptional activity. On
the other hand SUFU-DC is a less effective transcriptional
inhibitor, but elicits a reduction of the GLI1FL protein levels
(Figs 3B and 6). Thus, SUFU-DC, in line with its intrinsically lower
stability in human cells, may act as a scavenger by promoting
GLI1FL degradation instead of only shuttling GLI1FL to the
cytoplasm, as does SUFU-FL [3]. This scenario is supported by
the immunofluorescence data in which GLI1FL tends to localize
to punctate cytoplasmic densities when co-expressed with SUFU-
DC (Fig 7).
Moreover, specific knock-down of the SUFU-DC resulted in
increased protein levels of GLI1FL and activation of HH signaling
target genes (Fig 8), providing support for an in vivo function of this
variant as a regulator of the GLI1FL protein and consequently
HH signal transduction. This finding indicates that the relatively
weaker repression of GLI1FL activity by SUFU-DC, determined
by the over-expression analyses of Figs. 3–5, may be augmented by
the destabilization of the GLI1FL protein. Taken together, our
experimental data suggest that the mechanism of action of SUFU-
DC is fundamentally different from that of SUFU-FL, as
highlighted by the distinct effects on GLI1FL protein/activity.
In conclusion, our results provide support for the presence of
novel regulatory mechanisms within the HH signaling pathway,
which are linked to the alternative splicing of SUFU. Further
evaluation of the SUFU isoforms will be needed in order to unfold
additional complexities of their differential function and regula-
tion.
Materials and Methods
Cell Lines and Reagents
The NIH3T3 cell line, the Hek293 cell line, the alveolar
rhabdomyosarcoma (A-RMS) cell line RMS13 and the embry-
onal rhabdomyosarcoma (E-RMS) cell line RD were purchased
from ATCC (Manassas, VA, USA), the E-RMS cell lines JR-1
and Rh36 were kind gifts from P. Houghton (St. Jude Childrens
Research Hospital, USA), CCA was a kind gift from P-L Lollini
(University of Bologna, Italy), and CT-TC a kind gift from H.
Hosoi (Kyoto Prefectural University of Medicine, Japan.
Figure 4. Dose-dependent SUFU repression of GLI activity in Sufu2/2 MEFs. Different amounts of SUFU-FL or SUFU-DC FLAG-tagged
expression constructs were co-transfected with 8xGLIBS-luc and pRL-SV reporter plasmids, and the luciferase activity was measured. Error bars
indicate the standard deviation. NS, non-specific; co-transfection with 8xmutatedGLIBS-luc.
doi:10.1371/journal.pone.0037761.g004
SUFU Splice Variant
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37761Ptch12/2 MEFs was a kind gift from J. Taipale (University of
Helsinki, Finland), and Sufu2/2 mouse embryonic fibroblasts
(MEFs) were established by S. Teglund in our laboratory [8].
cDNA panels (Human tissues and human tumor cell lines) were
purchased from BD Biosciences (San Jose, CA, USA). MG-132
was purchased from Calbiochem (San Diego, CA, USA).
Real-time RT-PCR
Total RNA from cells was prepared with the RNeasy kit
(Qiagen, Hamburg, Germany) followed by cDNA synthesis with
random (N6) primers (New England Biolabs, Ipswich, MA, USA)
and Superscript II (Invitrogen, Carlsbad, CA, USA). Real-time
RT-PCR was performed with Power SYBR Green (Applied
Biosystems, Foster City, CA, USA) on a 7500 Fast real-time PCR
Figure 5. Dose-dependent SUFU repression of GLI1 activity in constitutively active Ptch12/2 MEFs. Different amounts of Myc-tagged
SUFU-FL or SUFU-DC expression constructs were co-transfected with 50 ng GLI1 expression constructs (Panel A, GLI1FL; panel B, GLI1DN), 12xGLIBS-
luc and pRL-SV reporter plasmids, and the luciferase activity was measured. Error bars indicate the standard deviation. Note the increased capacity of
SUFU-DC relative to SUFU-FL in inhibiting GLI1DN transcriptional activity.
doi:10.1371/journal.pone.0037761.g005
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37761Figure 6. SUFU-DC but not SUFU-FL reduces GLI1FL protein levels. A, GLI1FL was introduced into Hek293 cells together with either SUFU-FL
or SUFU-DC FLAG-tagged expression constructs, as indicated. Soluble protein fractions were run on a SDS-PAGE gel, followed by Western blotting,
and detected by a GLI1 antibody. Vinculin staining was used as a loading control. B, Quantification of average GLI1FL protein levels in this and in an
additional repeat experiment. Note that SUFU-DC but not SUFU-FL elicits a reduction of GLI1FL protein. C, SUFU-FL (FL) or SUFU-DC( DC) was
introduced into RMS13 cells, with or without 10 mM MG-132 treatment for 6 hours. Soluble protein fractions were run on a SDS-PAGE gel, followed by
Western blotting, and detected by a GLI1 antibody. Vinculin staining was used as a loading control. D, Quantification of average GLI1FL protein levels
in this and in an additional repeat experiment. Note that SUFU-DC but not SUFU-FL elicits a detectable reduction of GLI1FL protein and that MG-132
treatment confers an increase in GLI1FL protein.
doi:10.1371/journal.pone.0037761.g006
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37761Figure 7. Subcellular localization of SUFU-FL and SUFU-DC in Hek293 cells. The transfected SUFU and/or GLI1FL constructs were detected
using Myc and FLAG antibodies by confocal microscopy. A, Individual transfections of Myc-tagged SUFU-FL or SUFU-DC and FLAG-tagged GLI1FL
constructs. B, Co-transfections of GLI1FL with the SUFU-FL (FL) or the SUFU-DC( DC) construct. Two representative images from each co-transfection
are shown. The nuclei are stained with the marker DRAQ5 (blue signal). Note that GLI1FL co-localizes with SUFU-DC in aggregate/clump structures in
the cytoplasm.
doi:10.1371/journal.pone.0037761.g007
Figure 8. Knock-down of SUFU-DC expression in RMS13 cells results in increased GLI1FL protein and up-regulation of HH targets.
A, Real-time RT-PCR analysis of the relative expression of SUFU-DC and SUFU-FL following transfection of the sh4, sh5 or shEGFP construct. B,
Western blot analysis of soluble protein fractions with a GLI1 antibody following transfection of the sh4, sh5 or shEGFP construct. A quantification of
the protein levels is shown to the right. C, Real-time RT-PCR analysis of the relative expression of HHIP, GLI1, PTCH1-1B and PTCH1-1C following
transfection of the sh4, sh5 or shEGFP construct. In both the A and C panels the expression levels relative to the EGFP control, normalized to the
mean expression of the housekeeping genes RPLPO and TBP, are shown. Error bars indicate the standard deviation. *, Statistical significant, p,0,05,
compared with control (Student’s t test). Note that the more effective the knock-down of SUFU-DC, the higher the increase of GLI1FL protein and the
expression of HH signaling target genes.
doi:10.1371/journal.pone.0037761.g008
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SUFU–Forward: 59-TGCCACTGAGGAGCATCCTTACGC;
SUFU-FL–Reverse: 59-TTCAGGCCAGCTGTACTCTTTGG-
GAAG; SUFU-DC–Reverse: 59-TCAGGGCAGAAA-
GACGTTCCAGGAC. Additional primer sets are found in the
Table S1. mRNA expression levels were normalized against the
housekeeping genes RPLPO and TBP, and the relative units after
assigning RPLPO or the average of RPLPO and TBP expression to
1 are shown. Individual experiments were performed at least in
triplicate and the data from a representative experiment are
shown. Statistical significance was evaluated using a two-tailed,
unpaired Student’s t test and p,0,05 was considered statistically
significant.
Western Blot
Proteins were extracted and separated on 15% or 7% SDS-
PAGE essentially as described [21]. SUFU was detected with a
rabbit polyclonal antibody (C81H7), GLI1 with a rabbit
polyclonal antibody, both from Cell Signaling (Danvers, MA,
USA), FLAG with a mouse monoclonal antibody (M2) from
Sigma-Aldrich (St. Louis, MO, USA), GLI2 with a rabbit
polyclonal antibody from Aviva Systems Biology (San Diego,
CA, USA) and vinculin with a mouse monoclonal antibody
(V9131) from Sigma-Aldrich. Horseradish peroxidase-conjugated
anti-rabbit IgG or anti-mouse IgG (GE Healthcare, Little
Chalfont, Buckinghamshire, UK) was used as the secondary
antibody, followed by detection of the proteins with the Western
Lightning Western blot Chemiluminescence Reagent Plus (Perki-
nElmer Life Sciences, Waltham, MA, USA). Individual experi-
ments were performed at least in duplicate and the data from a
representative experiment are shown. Protein levels were quanti-
fied using the Fiji software (ImageJ/NIH).
Expression Constructs and Transfection
Expression and reporter constructs have been described
elsewhere [3,18]. The SUFU-FL-EYFP was a kind gift from M.
Lauth, the GLI2FL was a kind gift from E. Roessler and the
GLI2DN was a kind gift from F. Aberger. The Myc-SUFU-DC
expression construct was generated by replacement of the Xba1
and NspE1 digested Myc-SUFU-FL expression construct with a
RT/PCR product amplified by the primer set 59-GCTTCTA-
GAATAGGTTCAGAGTTGT and 59-ACCAATCAACCCT-
CAGCGGCAGAAT. The SUFU-FL-FLAG and SUFU-DC-
FLAG constructs were generated from the SUFU-FL-EYFP
plasmid. Following BspE1/Xba1 double digestion, ligation of
PCR products generated by the primer sets SUFU-Forward 59-
ACCAATCAACCCTCAGCGGCAGAAT and either FLAG-
SUFU-FL-Reverse 59-GCTTCTAGACTACTTGTCATCGT-
CGTCCTTGTAATCGTGTAGCGGACTGTCG or FLAG-
SUFU-DC-Reverse 59- GCTTCTAGACTACTTGTCATCG-
TCGTCCTTGTAATCGAGTTGTAACCAGGGT were per-
formed. For all expression constructs the pCMV vector was used.
The expression constructs and the appropriate reporter construct
were transfected into cultured cells using FuGENE6 (Roche
Diagnostics, Mannheim, Germany) or Lipofectamine 2000 (In-
vitrogen). Expression of the SUFU variants in E.coli is described in
Methods S1.
Reporter Assays
Luciferase reporter assays were performed essentially as
described previously [18,21]. All experiments were analyzed
independently three times, and a representative experiment is
shown.
Immunofluorescence
Hek293 cells were plated in 4-well poly-d-lysine-coated dishes,
and transfected 24 hours later with Myc-tagged SUFU constructs
and GLI1FL-FLAG. 48 h after transfection, cells were fixed,
permeabilized, incubated with anti-FLAG (Sigma-Aldrich) and/or
anti-Myc (Santa Cruz; sc-789) overnight and fluorescently labeled
with Alexa Fluor dye-conjugated secondary antibodies (Molecular
Probes, Eugene, OR, USA). Imaging of the immunostained cells
was performed using a Zeiss LSM510 confocal microscope.
Individual experiments were performed at least in triplicate and
the data from a representative experiment are shown.
RNA Interference
Two shRNA constructs (sh4 and sh5) targeting SUFU-DC were
designed using sequences from SUFU exon 10a and the Insert
Design Tool for the pSilencer Vectors (Ambion, Austin, TX,
USA). As a negative control, a shRNA targeting the Enhanced
Green Fluorescent Protein (EGFP), shEGFP, was also designed.
Complementary oligonucleotides with BamHI and HindIII sites at
the ends were ordered from Sigma-Aldrich with the following
sequences; sh4: 59-CCTATCCTCGGAGCTCTGCTTCAAGA-
GAGCAGAGCTCCGAGGATAGGTT, sh5: 59-TTTTCAG-
CAGCTCAAGAACTTCAAGAGAGTTCTTGAGCTGCTGA-
AAATT, shEGFP: 59-GAAGCAGCACGACTTCTTCTTCAA-
GAGAGAAGAAGTCGTGCTGCTTCAT and cloned into the
pSilencer 4.1-CMVpuro vector. All constructs were verified by
sequencing. RMS13 cells were transfected with the shRNA
constructs and subjected to puromycin (1 mg/mL) selection for 4
days, followed by RNA isolation and real-time RT-PCR.
Supporting Information
Figure S1 Heterologous expression of SUFU variants in
E. coli. SUFU-FL (upper panel) and SUFU-DC (lower panel)
constructs were purified from E. coli as described above.
Chromatograms of the last purification step, size-exclusion
chromatography, are shown. Open arrows indicate peaks
corresponding to protein eluted with the void volume (aggregated
form), while filled arrows indicate peaks corresponding to
monomeric (soluble form) protein fractions. Note the decreased
amount of SUFU-DC relative to SUFU-FL in the soluble fraction.
(PDF)
Figure S2 The Western blot of Fig 6A was stripped and
incubated with a GLI2 antibody. Note that the levels of
endogenous GLI2 remain unchanged irrespective of the introduc-
tion of SUFU-DC or SUFU-FL.
(PDF)
Figure S3 Western blot analysis of SUFU protein levels
after shRNA down-regulation. shEGFP, sh5 or sh4 constructs
were transfected into RMS13 cells, followed by SDS-PAGE gel
electrophoresis and Western blot analysis by a SUFU antibody.
Both a short and a long exposure are shown. SUFU-DCi s
indicated by an arrow. Vinculin was used as a loading control. A
quantification of the SUFU-DC protein levels relative to SUFU-
FL is shown below the blot, revealing a 33% reduction of SUFU-
DC by sh5 RNA treatment.
(PDF)
Methods S1 Heterologous protein expression in E.coli
and purification.
(PDF)
Table S1 Sequence of PCR primers.
(PDF)
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